title: CpG oligodeoxynucleotides discriminately enhance binding capacity of human naïve B cells to  Hepatitis B virus  epitopes.
abstract: CpG oligodeoxynucleotides (CpG ODN) have the potential to enhance the antigen-presenting cells function of human naïve B cells. In this study, we aim to define the effect of CpG ODNs on the binding capacity of human naïve B cells for different Hepatitis B virus (HBV) epitopes. Three HLA-A2 restricted epitopes were selected to incubate with CpG ODN-primed human naïve B cells. Binding capacity for each epitope and expression of CD80, CD86, class I major histocompatibility complex (MHC), and class II MHC of naïve B cells was tested, respectively, by flow cytometry. CpG ODNs, especially ODN 2216, enhanced the binding capacity of human naïve B cells for HBV epitopes (p < 0.01), and induced markedly higher expression of CD80, CD86, class I MHC, and class II MHC. The binding capacity of CpG-treated naive B cells for each epitope was significantly different. In all the 3 subjects, CpG ODN 2216-primed naïve B cells showed the highest binding ability for Env172-180 compared with the other epitopes with a high expression of co-stimulatory and MHC molecules. CpG ODN showed the potential to selectively enhance the binding capacity of human naïve B cells for HBV epitopes. These results suggest new strategies for development of vaccine design.
authors.affiliation: Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR China.
authors.forename: Jian-ying
authors.initials: JY
authors.lastname: Bai
authors.forename: Yong-tao
authors.initials: YT
authors.lastname: Yang
authors.forename: Rong
authors.initials: R
authors.lastname: Zhu
authors.forename: Yi-qin
authors.initials: YQ
authors.lastname: Wang
authors.forename: Yin
authors.initials: Y
authors.lastname: Tian
authors.forename: Xiao-huan
authors.initials: XH
authors.lastname: Li
authors.forename: Rong-quan
authors.initials: RQ
authors.lastname: Wang
mesh_terms: D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology / Q000378:metabolism; D006515:Hepatitis B virus / Q000276:immunology / Q000378:metabolism*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000378:metabolism*
chemical_list: C408982:CPG-oligonucleotide; D000939:Epitopes; D015789:HLA-A2 Antigen; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D009838:Oligodeoxyribonucleotides